Literature DB >> 33479160

The SEE Study: Safety, Efficacy, and Equity of Implementing Autonomous Artificial Intelligence for Diagnosing Diabetic Retinopathy in Youth.

Risa M Wolf1, T Y Alvin Liu2, Chrystal Thomas1, Laura Prichett3, Ingrid Zimmer-Galler2, Kerry Smith2, Michael D Abramoff4,5,6,7,8, Roomasa Channa9,10.   

Abstract

OBJECTIVE: Diabetic retinopathy (DR) is a leading cause of vision loss worldwide. Screening for DR is recommended in children and adolescents, but adherence is poor. Recently, autonomous artificial intelligence (AI) systems have been developed for early detection of DR and have been included in the American Diabetes Association's guidelines for screening in adults. We sought to determine the diagnostic efficacy of autonomous AI for the diabetic eye exam in youth with diabetes. RESEARCH DESIGN AND METHODS: In this prospective study, point-of-care diabetic eye exam was implemented using a nonmydriatic fundus camera with an autonomous AI system for detection of DR in a multidisciplinary pediatric diabetes center. Sensitivity, specificity, and diagnosability of AI was compared with consensus grading by retinal specialists, who were masked to AI output. Adherence to screening guidelines was measured before and after AI implementation.
RESULTS: Three hundred ten youth with diabetes aged 5-21 years were included, of whom 4.2% had DR. Diagnosability of AI was 97.5% (302 of 310). The sensitivity and specificity of AI to detect more-than-mild DR was 85.7% (95% CI 42.1-99.6%) and 79.3% (74.3-83.8%), respectively, compared with the reference standard as defined by retina specialists. Adherence improved from 49% to 95% after AI implementation.
CONCLUSIONS: Use of a nonmydriatic fundus camera with autonomous AI was safe and effective for the diabetic eye exam in youth in our study. Adherence to screening guidelines improved with AI implementation. As the prevalence of diabetes increases in youth and adherence to screening guidelines remains suboptimal, effective strategies for diabetic eye exams in this population are needed.
© 2021 by the American Diabetes Association.

Entities:  

Year:  2021        PMID: 33479160     DOI: 10.2337/dc20-1671

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  5 in total

Review 1.  Pediatric Diabetic Retinopathy: Updates in Prevalence, Risk Factors, Screening, and Management.

Authors:  Tyger Lin; Rose A Gubitosi-Klug; Roomasa Channa; Risa M Wolf
Journal:  Curr Diab Rep       Date:  2021-12-13       Impact factor: 4.810

2.  A reimbursement framework for artificial intelligence in healthcare.

Authors:  Michael D Abràmoff; Cybil Roehrenbeck; Sylvia Trujillo; Juli Goldstein; Anitra S Graves; Michael X Repka; Ezequiel Zeke Silva Iii
Journal:  NPJ Digit Med       Date:  2022-06-09

3.  Potential reduction in healthcare carbon footprint by autonomous artificial intelligence.

Authors:  Risa M Wolf; Michael D Abramoff; Roomasa Channa; Chris Tava; Warren Clarida; Harold P Lehmann
Journal:  NPJ Digit Med       Date:  2022-05-12

Review 4.  Digital innovations for retinal care in diabetic retinopathy.

Authors:  Stela Vujosevic; Celeste Limoli; Livio Luzi; Paolo Nucci
Journal:  Acta Diabetol       Date:  2022-08-12       Impact factor: 4.087

5.  Clinical and Demographic Factors Associated With Diabetic Retinopathy Among Young Patients With Diabetes.

Authors:  Michael L Ferm; Daniel J DeSalvo; Laura M Prichett; James K Sickler; Risa M Wolf; Roomasa Channa
Journal:  JAMA Netw Open       Date:  2021-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.